• Biome records $195k EBITDA for Q3
• Biome achieves 41% increase in sales revenue to $4.51m
• Biome expects to report first full year net profit for FY25

Biome Australia Limited (ASX: BIO) has reported positive results for the quarter ended 31 March 2025, including $195k EBITDA, a net operating cash inflow of $123k, and a 41% increase in sales revenue to $4.51m compared to the prior corresponding period. The company also recorded a gross margin of 61% for Q3 and had a cash balance of $2.7m as at 31 March 2025. Biome has achieved positive EBITDA over five consecutive quarters and expects to report its first net profit in FY25. The company is preparing for the launch of its new Activated Therapeutics brand and product range in Q4. Biome received record cash receipts of $4.91m in Q3, up 61% versus the prior corresponding period and 13% versus Q2. The company notes that the pharmacy industry is predicting a record cold and flu season in 2025, which is often a strong signal for growth in the probiotic category through the winter months.

Biome expects to report its first full year net profit for FY25.